Lunai Bioworks Raises $20M via Preferred Stock to Acquire Dual BBB Delivery IP
Lunai Bioworks completed a $20 million Series B Preferred equity issuance to acquire two CNS-focused IP portfolios, adding a BBB-crossing prodrug system and nose-to-brain delivery technology. The transaction boosts stockholders’ equity above the $2.5 million Nasdaq threshold and expands the company’s Alzheimer’s, combination therapy and biodefense platforms with new 505(b)(2) development pathways.
1. Series B Preferred Issuance and Equity Compliance
Lunai completed a $20 million issuance of Series B Preferred Stock to meet Nasdaq Listing Rule 5550(b)(1) stockholders’ equity requirement, raising equity above the $2.5 million minimum and maintaining compliance pending the Panel’s formal determination of continued compliance.
2. Acquisition of Dual CNS Delivery IP
The equity infusion funded acquisition of two central nervous system-focused intellectual property portfolios, integrating a blood-brain barrier-crossing prodrug system and a nose-to-brain (N2B) delivery pathway to enhance therapeutic access and enable combinatorial strategies.
3. Expanded Therapeutic and Funding Pathways
The added IP bolsters Lunai’s Alzheimer’s and multi-agent therapy pipeline, supports 505(b)(2) reformulation pathways for faster development, and strengthens biodefense countermeasure capabilities, positioning the company for partnerships, licensing agreements and non-dilutive funding opportunities.